文献速递脑血管病

短暂性脑缺血发作和缺血性卒中后脑微出血患者的抗血小板治疗:两项大型队列及更新系统综述

Antiplatelet Treatment After Transient Ischemic Attack and Ischemic Stroke in Patients With Cerebral Microbleeds in 2 Large Cohorts and an Updated Systematic Review.
PubMed 文献 · Stroke · 2018-05-10

在两项独立前瞻性队列(牛津血管研究以白人为主,香港大学研究以华人为主)中,短暂性脑缺血发作/缺血性卒中患者无论微出血负荷如何均常规启动抗血小板治疗。微出血≥5个的患者第一年内缺血性卒中及冠脉事件风险高于脑出血和颅外大出血,但一年后出血风险与缺血事件风险相当。

要点

  • 微出血≥5个的患者第一年缺血性卒中及冠脉事件风险为11.6%,高于脑出血和颅外大出血的3.9%。
  • 一年后出血风险(11.2%)与缺血事件风险(12.0%)相当。
  • 微出血≥5个组中82%的脑出血为致残/致死性,而缺血性卒中为40%(P=0.035)。

核心结论

  • 在白人和华人微出血≥5个的患者中,短暂性脑缺血发作/缺血性卒中后第一年内停用抗血小板药物可能不合适,但此后脑出血风险可能超过任何获益。

研究设计与样本

  • 两项独立前瞻性队列:牛津血管研究(以白人为主)和香港大学研究(以华人为主),共随访7433患者年。
  • 抗血小板治疗无论微出血负荷如何均常规启动,按微出血负荷(0个 vs 1、2-4、≥5个)分层,并校正年龄、性别和血管危险因素。

主要发现

  • 华人队列微出血更常见(1003例中450例 vs 1080例中165例;P<0.0001),但随访期间风险关联相似。
  • 1811例服用抗血小板药物患者中,大颅外出血风险与微出血负荷无关(P趋势=0.87),但5年脑出血风险与微出血负荷陡峭相关(P趋势<0.0001),15例脑出血中11例(73%)发生于微出血≥5个的140/1811例(7.7%)患者。
  • 缺血性卒中风险也随微出血负荷增加(P趋势=0.013),第一年内即使微出血≥5个的患者,缺血性卒中及冠脉事件风险(11.6%)仍高于脑出血和大颅外出血(3.9%)。
  • 一年后出血风险(11.2%)与缺血事件风险(12.0%)相当。
  • 微出血负荷与缺血性卒中风险的关联主要归因于非致残事件(P趋势=0.007),而与脑出血的关联由致残/致死事件解释(P趋势<0.0001;微出血≥5个组:致残/致死性脑出血82% vs 致残/致死性缺血性卒中40%;P=0.035)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In patients with transient ischemic attack/ischemic stroke, microbleed burden predicts intracerebral hemorrhage (ICH), and ischemic stroke, but implications for antiplatelet treatment are uncertain. Previous cohort studies have had insufficient follow-up to assess the time course of risks, have not stratified risks by antithrombotic use, and have not reported extracranial bleeds or functional outcome of ICH versus ischemic stroke. METHODS: In 2 independent prospective cohorts with transient ischemic attack/ischemic stroke (Oxford Vascular Study/mainly white; University of Hong Kong/mainly Chinese), antiplatelet treatment was started routinely irrespective of microbleed burden. Risks, time course and outcome of ICH, extracranial bleeds, and recurrent ischemic events were determined and stratified by microbleed burden (0 versus 1, 2-4, and ≥5), adjusting for age, sex, and vascular risk factors. RESULTS: Microbleeds were more frequent in the Chinese cohort (450 of 1003 versus 165 of 1080; P<0.0001), but risk associations were similar during 7433 patient-years of follow-up. Among 1811 patients on antiplatelet drugs, risk of major extracranial bleeds was unrelated to microbleed burden (Ptrend=0.87), but the 5-year risk of ICH was steeply related (Ptrend<0.0001), with 11 of 15 (73%) of ICH in 140 of 1811 (7.7%) patients with ≥5 microbleeds. However, risk of ischemic stroke also increased with microbleed burden (Ptrend=0.013), such that risk of ischemic stroke and coronary events exceeded ICH and major extracranial bleeds during the first year, even among patients with ≥5 microbleeds (11.6% versus 3.9%). However, this ratio changed over time, with risk of hemorrhage (11.2%) matching that of ischemic events (12.0%) after 1 year. Moreover, whereas the association between microbleed burden and risk of ischemic stroke was due mainly to nondisabling events (Ptrend=0.007), the association with ICH was accounted for (Ptrend<0.0001) by disabling/fatal events (≥5 microbleeds: 82% disabling/fatal ICH versus 40% disabling/fatal ischemic stroke; P=0.035). CONCLUSIONS: In white and Chinese patients with ≥5 microbleeds, withholding antiplatelet drugs during the first year after transient ischemic attack/ischemic stroke may be inappropriate. However, the risk of ICH may outweigh any benefit thereafter.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lau KK, Lovelock CE, Li L, et al. Antiplatelet Treatment After Transient Ischemic Attack and Ischemic Stroke in Patients With Cerebral Microbleeds in 2 Large Cohorts and an Updated Systematic Review. Stroke. 2018. PMID: 29748422. doi:10.1161/STROKEAHA.117.020104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。